ReviewCardiovascular therapeutics2011
5-hydroxtryptamine receptors in systemic hypertension: an arterial focus.
Review in Cardiovascular therapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 73 citations in OpenAlex.
- Bilobalide increases SKBMC complementary medicine and therapies · 2026Article
- Review
- Smooth Muscle LRRC8A Knockout Preserves Vascular Function in Ang II Hypertension.Hypertension (Dallas, Tex. : 1979) · 2026Article
- Role of central and peripheral serotonin in liver physiology and diseases.Theranostics · 2026Review
- Beyond the Microbiome: The Gut's Role in Hypertension.Function (Oxford, England) · 2025Review
- The Coordinated Changes in Platelet Glycan Patterns with Blood Serotonin and Exosomes.International journal of molecular sciences · 2024Review
- Article
- Involvement of neuronal factors in tumor angiogenesis and the shaping of the cancer microenvironment.Frontiers in immunology · 2024Review
- Activation of renal vascular smooth muscle TRPV4 channels by 5-hydroxytryptamine impairs kidney function in neonatal pigs.Microvascular research · 2023Article
- Serotonergic Modulation of Neurovascular Transmission: A Focus on Prejunctional 5-HT Receptors/Mechanisms.Biomedicines · 2023Review
- Telotristat ethyl reverses myxomatous changes in mice mitral valves.Frontiers in cardiovascular medicine · 2022Article
- Serotonin Pathway in Cancer.International journal of molecular sciences · 2021Review
- Mechanism of contractile dysfunction induced by serotonin in coronary artery in spontaneously hypertensive rats.Naunyn-Schmiedeberg's archives of pharmacology · 2020Article
- The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database.International journal of obesity (2005) · 2020Article
- Deletion of murine slc29a4 modifies vascular responses to adenosine and 5-hydroxytryptamine in a sexually dimorphic manner.Physiological reports · 2020Article
- Postnatal outcomes in lambs exposed antenatally and acutely postnatally to fluoxetine.Pediatric research · 2019Article
- Fenfluramine-induced PVAT-dependent contraction depends on norepinephrine and not serotonin.Pharmacological research · 2019Article
- Management of severe arterial hypertension associated with serotonin syndrome: a case report analysis based on systematic review techniques.Therapeutic advances in psychopharmacology · 2019Article
- Inhibition of 5-Hydroxytryptamine Receptor 2B Reduced Vascular Restenosis and Mitigated the β-Arrestin2-Mammalian Target of Rapamycin/p70S6K Pathway.Journal of the American Heart Association · 2018Article
- Multiple activation mechanisms of serotonin-mediated contraction in the carotid arteries obtained from spontaneously hypertensive rats.Pflugers Archiv : European journal of physiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
backgroundSerotonin (5-hydroxytryptamine [5-HT]) was named for its isolation from blood serum (sero-) and ability to contract smooth muscle (-tonin). Thus, its relationship with the cardiovascular system began with its discovery.
aimsThis review will focus on the effects of 5-HT and its receptors in the vasculature, with a focus on their involvement in high blood pressure (hypertension). Two seemingly contradictory bodies of evidence exist that make it difficult to assign any one function to 5-HT in vascular control of blood pressure.
resultsIn vitro, 5-HT is an established vasoconstrictor, the effects of which are amplified in hypertension. By contrast, 5-HT (or its precursor 5-hydroxytryptophan) lowers blood pressure when given chronically in vivo. We will discuss ideas that might help us understand these differences, discuss relatively new pharmacology parameters (e.g. biased, inverse agonism) as they pertain to 5-HT receptors, and pose questions that are vital to answer so as to understand the role played by 5-HT in control of blood pressure, especially as it pertains to vascular function.
conclusionsOur goal is to understand if the actions of 5-HT in hypertension are physiologically and clinically relevant. The community understands 5-HT has complex cardiovascular effects, and clinical studies have proven equivocal in terms of the involvement of 5-HT. This article provides a balanced view of evidence/literature that illustrates involvement of 5-HT in hypertension as controversial. It contributes new pharmacological knowledge of 5-HT compounds, and poses timely questions as to how this field can move forward. The take home message is that the cardiovascular effects of 5-HT are markedly complex such that we have not yet answered the question of whether 5-HT is beneficial or detrimental to hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.